troglitazone has been researched along with Obesity in 96 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients." | 9.10 | Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. ( Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO, 2003) |
| "Troglitazone decreases insulin resistance and improves glucose tolerance in obese subjects with either impaired or normal glucose tolerance." | 9.07 | Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. ( Beerdsen, P; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, J, 1994) |
| "Body weight and BP decreased significantly in the diet group but not in the troglitazone group at the end of the intervention periods." | 7.71 | Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. ( Kamide, K; Kawano, Y; Minami, J; Tsunoda, S, 2002) |
| "Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy." | 7.70 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. ( Elkind-Hirsch, KE; McWilliams, RB, 1999) |
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 7.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "Seventy-eight patients with type 2 diabetes adequately controlled with glibenclamide were randomly allocated to a troglitazone (400 mg/d)-added group (n = 40) or a control group without placebo (n = 38) and monitored for 24 weeks." | 6.70 | Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. ( Hata, S; Ikemoto, S; Inoue, Y; Katoh, S; Matsushima, M; Tajima, N; Yokoyama, J, 2001) |
| "Insulin resistance is associated with a decreased vasodilator response to insulin." | 6.69 | Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. ( Lutterman, JA; Ong, MK; Smits, P; Tack, CJ, 1998) |
| "Troglitazone treatment decreased adipose tissue GPX activity and abolished overproduction of TNF-alpha in OLETF rats." | 5.31 | Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue. ( Asayama, K; Dobashi, K; Hayashibe, H; Kodera, K; Nakane, T; Nakazawa, S; Uchida, N, 2001) |
| "This troglitazone-induced increase in the expression of aP2 and FAT/CD36 was markedly enhanced in the liver in ob/ob mice." | 5.31 | Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the li ( Beigneux, A; Feingold, KR; Grunfeld, C; Memon, RA; Moser, AH; Nonogaki, K; Tecott, LH, 2000) |
| "Troglitazone has been shown to improve peripheral insulin resistance in type 2 diabetic patients and animal models." | 5.31 | Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. ( Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Nakatani, K; Sumida, Y; Tanaka, T; Yano, Y, 2002) |
| "We tested the effect-modifying role of Pro12Ala on the 1 year change in obesity-related traits in a randomised clinical trial of treatment with metformin (n = 989), troglitazone (n = 363) or lifestyle modification (n = 1,004) vs placebo (n = 1,000) for diabetes prevention in high-risk individuals." | 5.12 | The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. ( Altshuler, D; Delahanty, L; Florez, JC; Franks, PW; Hanson, RL; Jablonski, KA; Kahn, SE; Knowler, WC, 2007) |
| " Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients." | 5.10 | Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. ( Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO, 2003) |
| "In obese subjects, treatment with troglitazone improves insulin sensitivity, increases the ratio of large buoyant to small dense LDL, and appears to enhance the resistance of the LDL particle to oxidation." | 5.08 | Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. ( Demacker, PN; Smits, P; Stalenhoef, AF; Tack, CJ, 1998) |
| "Troglitazone decreases insulin resistance and improves glucose tolerance in obese subjects with either impaired or normal glucose tolerance." | 5.07 | Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. ( Beerdsen, P; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, J, 1994) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| " Troglitazone attenuated HOMA-IR and ameliorated proteinuria, but did not affect body weight, creatinine clearance, or blood pressure." | 3.73 | Insulin resistance contributes to obesity-related proteinuria. ( Iwasawa, H; Matsumoto, H; Nagaoka, Y; Nakao, T; Okada, T; Tomaru, R; Wada, T, 2005) |
| "Body weight and BP decreased significantly in the diet group but not in the troglitazone group at the end of the intervention periods." | 3.71 | Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. ( Kamide, K; Kawano, Y; Minami, J; Tsunoda, S, 2002) |
| " Compared with lean controls, untreated obese rats had significantly higher body weights, fat pad masses, plasma triglycerides, free fatty acids and leptin levels (for all P < 0." | 3.71 | Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. ( Doyle, PJ; Naderali, EK; Pickavance, LC; Wilding, JP; Williams, G, 2001) |
| " In the present study, we used Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which exhibit hypertension, obesity, severe hyperglycemia and hypertriglyceridemia, and are thus considered an animal model of atherogenic disease, to test the effects of oral administration of troglitazone (200 mg/kg) on renal klotho mRNA expression and endothelial function." | 3.71 | Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. ( Kanai, H; Kurabayashi, M; Kuro-o, M; Nabeshima, Y; Nagai, R; Nakamura, T; Saito, Y; Sumino, H; Takeda, S; Yamagishi, T, 2001) |
| "We studied the effect of troglitazone on the plasma concentrations of homocysteine (tHcy), the erythrocyte and hepatic concentrations of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH), and the hepatic activities of cystathionine-beta-synthase (C beta S) and methylenetetrahydrofolate reductase (MTHFR) in lean and fatty Zucker rats (a model of insulin resistance)." | 3.71 | The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. ( Desouza, C; Dicker-Brown, A; Fonseca, V; Keebler, M; McNamara, DB; Murthy, SN; Poirier, LA, 2002) |
| "Both the lard and sucrose enrichment increased SBP and body weight compared with controls." | 3.70 | Dietary fat-induced increase in blood pressure and insulin resistance in rats. ( Hotta, N; Iguchi, A; Miura, H; Nakamura, J; Tamagawa, T; Tamaya, N; Uemura, K; Yoshioka, S, 2000) |
| "An open study comparing the effects of weight reduction by low-energy diet and treatment with troglitazone, an insulin-sensitizing agent." | 3.70 | Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients. ( Kawano, Y; Minami, J; Okuda, N; Omae, T; Takishita, S, 2000) |
| " We tested the hypothesis that troglitazone, which improves insulin sensitivity and lowers plasma insulin levels in insulin-resistant obese subjects and patients with type 2 diabetes, would also lower circulating PAI-1 antigen concentrations and activity." | 3.70 | Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. ( Kruszynska, YT; Olefsky, JM; Sobel, BE; Yu, JG, 2000) |
| "Obesity is often accompanied by a decreased ability of insulin to stimulate glucose uptake and glycogenesis in skeletal muscle." | 3.70 | Assessment of human muscle glycogen synthesis and total glucose content by in vivo 13C MRS. ( Heerschap, A; Smits, P; Tack, CJ; Van Den Bergh, AJ; Van Den Boogert, HJ; Vervoort, G, 2000) |
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 3.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy." | 3.70 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. ( Elkind-Hirsch, KE; McWilliams, RB, 1999) |
| " Troglitazone is an insulin-sensitizing thiazolidinedione, which improves hepatic and skeletal muscle insulin resistance in NIDDM and obesity." | 3.69 | Effect of troglitazone on leptin production. Studies in vitro and in human subjects. ( Caro, JF; Considine, RV; Nolan, JJ; Nyce, MR; Olefsky, JM, 1996) |
| "Metformin treatment had no significant impact on GSK-3 protein expression in either adipocytes or skeletal muscle." | 2.72 | Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. ( Baxi, S; Christiansen, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, S; Nikoulina, SE; Oh, DK, 2006) |
| "Troglitazone treatment increased serum adiponectin levels nearly threefold." | 2.71 | Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. ( Aroda, V; Bandukwala, R; Baxi, S; Carter, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, SR; Phillips, SA, 2003) |
| "Seventy-eight patients with type 2 diabetes adequately controlled with glibenclamide were randomly allocated to a troglitazone (400 mg/d)-added group (n = 40) or a control group without placebo (n = 38) and monitored for 24 weeks." | 2.70 | Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. ( Hata, S; Ikemoto, S; Inoue, Y; Katoh, S; Matsushima, M; Tajima, N; Yokoyama, J, 2001) |
| "Seven obese patients with type 2 diabetes were treated with troglitazone (400 mg/day) for 4 weeks." | 2.70 | Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? ( Aljada, A; Assian, E; Dandona, P; Garg, R; Ghanim, H; Hamouda, W; Mohanty, P, 2001) |
| "Insulin resistance is associated with a decreased vasodilator response to insulin." | 2.69 | Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. ( Lutterman, JA; Ong, MK; Smits, P; Tack, CJ, 1998) |
| "The prevalence of type 2 diabetes is increasing due to a combination of factors: increasing lifespan, sedentary lifestyle, excessive intake of high energy foods, increasing prevalence of overweight/obese people." | 2.41 | Prevention of type 2 diabetes. ( Lai, LC, 2002) |
| "NIDDM is even more common in the elderly and in minority population including Hispanic Americans, African Americans, Asian and Pacific Island Americans, and Native Americans." | 2.40 | [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]. ( Flórez, H, 1997) |
| "Troglitazone treatment improved ischemic tolerance by improving glucose metabolism in the myocardium of those rats." | 1.34 | Exacerbation of acidosis during ischemia and reperfusion arrhythmia in hearts from type 2 Diabetic Otsuka Long-Evans Tokushima Fatty rats. ( Anzawa, R; Horikoshi, K; Mochizuki, S; Seki, S; Taniguchi, M, 2007) |
| "Troglitazone (TGZ) treatment, beginning at 6 weeks of age, prevented the hyperglycemia, the hyperlipidemia, and the increase in 11beta-HSD-1." | 1.32 | Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. ( Agarwal, AK; Duplomb, L; Lee, Y; Park, BH; Takaishi, K; Unger, RH; Wang, MY, 2004) |
| "This troglitazone-induced increase in the expression of aP2 and FAT/CD36 was markedly enhanced in the liver in ob/ob mice." | 1.31 | Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the li ( Beigneux, A; Feingold, KR; Grunfeld, C; Memon, RA; Moser, AH; Nonogaki, K; Tecott, LH, 2000) |
| "Troglitazone treatment restored those alterations in PTPase activity in the particulate fraction and the amounts of LAR, PTP1B and SH-PTP2 in both fractions of visceral and epididymal adipose tissues of OLETF rats." | 1.31 | Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats. ( Homma, H; Honda, T; Ide, H; Kawakami, Y; Ohno, K; Sakaue, S; Tagami, S; Yoshimura, H, 2002) |
| " This provides a source of excess FAs that enter potentially toxic pathways of nonoxidative metabolism leading to apoptosis of certain tissues." | 1.31 | Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. ( Unger, RH; Zhou, YT, 2001) |
| "Troglitazone was less effective in controlling serum cholesterol and neuropathy." | 1.31 | Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. ( Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F, 2000) |
| "Troglitazone treatment decreased adipose tissue GPX activity and abolished overproduction of TNF-alpha in OLETF rats." | 1.31 | Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue. ( Asayama, K; Dobashi, K; Hayashibe, H; Kodera, K; Nakane, T; Nakazawa, S; Uchida, N, 2001) |
| "Troglitazone was given at a dose of 400 mg/day for < or = 6 months." | 1.31 | A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. ( Battle, EH; Caldwell, SH; Hespenheide, EE; Iezzoni, JC; Redick, JA; Sheppard, BL, 2001) |
| "Troglitazone has been shown to improve insulin sensitivity and thereby exert hypoglycemic effects in various animal models and humans with insulin resistance and diabetes." | 1.31 | Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. ( Akiyama, T; Fukumitsu, KI; Jia, DM; Nakamura, H; Otsuki, M; Tabaru, A, 2000) |
| "Troglitazone has been shown to improve peripheral insulin resistance in type 2 diabetic patients and animal models." | 1.31 | Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. ( Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Nakatani, K; Sumida, Y; Tanaka, T; Yano, Y, 2002) |
| "Troglitazone pre-treatment blocked the LPS-induced expression of iNOS in adipose tissue and the increase in serum nitrite concentration." | 1.31 | Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats. ( Asayama, K; Dobashi, K; Hayashibe, H; Kodera, K; Nakane, T; Nakazawa, S, 2000) |
| "Troglitazone treatment produced a significant rise in the metabolic clearance rate of glucose (MCR) during the 6-mU/kg BW/min insulin clamp study (19." | 1.30 | Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats. ( Kako, M; Li, L; Nakai, N; Ohsawa, I; Oshida, Y; Sato, J; Sato, Y; Shimomura, Y, 1999) |
| "Obesity is characterized by hyperinsulinemia, which reflects peripheral insulin resistance." | 1.29 | Antihypertensive effects of CS-045 treatment in obese Zucker rats. ( Fujiwara, T; Horikoshi, H; Ikeda, K; Koike, H; Nishino, H; Okuno, A; Shiraki, T; Wada, M; Yoshioka, S, 1993) |
| " Furthermore, 2-deoxyglucose uptake in CS-045-treated adipocytes was increased and the insulin dose-response curve was shifted to the left." | 1.27 | Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. ( Fujiwara, T; Horikoshi, H; Ushiyama, I; Yoshioka, S; Yoshioka, T, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.04) | 18.7374 |
| 1990's | 29 (30.21) | 18.2507 |
| 2000's | 64 (66.67) | 29.6817 |
| 2010's | 2 (2.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 2 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 2 |
| Banerjee, S | 1 |
| Talukdar, I | 1 |
| Banerjee, A | 1 |
| Gupta, A | 1 |
| Balaji, A | 1 |
| Aduri, R | 1 |
| Tsujino, Y | 1 |
| Venditti, EM | 1 |
| Bray, GA | 1 |
| Carrion-Petersen, ML | 1 |
| Delahanty, LM | 1 |
| Edelstein, SL | 1 |
| Hamman, RF | 1 |
| Hoskin, MA | 1 |
| Knowler, WC | 2 |
| Ma, Y | 1 |
| Tsunoda, S | 1 |
| Kamide, K | 1 |
| Minami, J | 2 |
| Kawano, Y | 2 |
| Tagami, S | 1 |
| Honda, T | 1 |
| Yoshimura, H | 1 |
| Homma, H | 1 |
| Ohno, K | 1 |
| Ide, H | 1 |
| Sakaue, S | 1 |
| Kawakami, Y | 1 |
| Kalderon, B | 1 |
| Mayorek, N | 1 |
| Ben-Yaacov, L | 1 |
| Bar-Tana, J | 1 |
| Hayashi, K | 1 |
| Kanda, T | 1 |
| Homma, K | 2 |
| Tokuyama, H | 1 |
| Okubo, K | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Kumagai, H | 1 |
| Saruta, T | 1 |
| Solignac, M | 1 |
| Paradisi, G | 1 |
| Steinberg, HO | 1 |
| Shepard, MK | 1 |
| Hook, G | 1 |
| Baron, AD | 1 |
| Phillips, SA | 1 |
| Ciaraldi, TP | 3 |
| Kong, AP | 2 |
| Bandukwala, R | 1 |
| Aroda, V | 1 |
| Carter, L | 1 |
| Baxi, S | 2 |
| Mudaliar, SR | 1 |
| Henry, RR | 4 |
| Sekino, N | 1 |
| Kashiwabara, A | 1 |
| Inoue, T | 1 |
| Kawasaki, T | 1 |
| Ogata, N | 1 |
| Sawashige, K | 1 |
| Yamanouchi, T | 1 |
| Angulo, P | 1 |
| Lai, LC | 1 |
| Levin, K | 1 |
| Hother-Nielsen, O | 1 |
| Henriksen, JE | 1 |
| Beck-Nielsen, H | 1 |
| Duplomb, L | 1 |
| Lee, Y | 4 |
| Wang, MY | 2 |
| Park, BH | 1 |
| Takaishi, K | 1 |
| Agarwal, AK | 1 |
| Unger, RH | 9 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Taylor, R | 1 |
| Laakso, M | 1 |
| Moreno Sánchez, D | 1 |
| Matsumoto, H | 1 |
| Nakao, T | 1 |
| Okada, T | 1 |
| Nagaoka, Y | 1 |
| Iwasawa, H | 1 |
| Tomaru, R | 1 |
| Wada, T | 1 |
| Oh, DK | 1 |
| Christiansen, L | 1 |
| Nikoulina, SE | 2 |
| Mudaliar, S | 2 |
| Zhang, J | 1 |
| Wright, W | 1 |
| Bernlohr, DA | 1 |
| Cushman, SW | 1 |
| Chen, X | 1 |
| Anzawa, R | 1 |
| Seki, S | 1 |
| Horikoshi, K | 1 |
| Taniguchi, M | 1 |
| Mochizuki, S | 1 |
| Seto, SW | 1 |
| Lam, TY | 1 |
| Leung, GP | 1 |
| Au, AL | 1 |
| Ngai, SM | 1 |
| Chan, SW | 1 |
| Kwan, YW | 1 |
| Sell, H | 1 |
| Eckel, J | 1 |
| Franks, PW | 1 |
| Jablonski, KA | 1 |
| Delahanty, L | 1 |
| Hanson, RL | 1 |
| Kahn, SE | 1 |
| Altshuler, D | 1 |
| Florez, JC | 1 |
| Nolan, JJ | 2 |
| Ludvik, B | 1 |
| Beerdsen, P | 1 |
| Joyce, M | 1 |
| Olefsky, J | 2 |
| Keen, H | 1 |
| Yoshioka, S | 3 |
| Nishino, H | 1 |
| Shiraki, T | 1 |
| Ikeda, K | 1 |
| Koike, H | 1 |
| Okuno, A | 1 |
| Wada, M | 1 |
| Fujiwara, T | 2 |
| Horikoshi, H | 2 |
| Olefsky, JM | 4 |
| Nyce, MR | 1 |
| Considine, RV | 1 |
| Caro, JF | 1 |
| Sakane, N | 1 |
| Yoshida, T | 2 |
| Kondo, M | 2 |
| Mantzoros, CS | 1 |
| Dunaif, A | 1 |
| Flier, JS | 1 |
| Flórez, H | 1 |
| Yoshioka, K | 2 |
| Yokoo, S | 1 |
| Shimabukuro, M | 4 |
| Zhou, YT | 5 |
| Katayama, S | 1 |
| Koyama, K | 1 |
| Arakawa, K | 1 |
| Inamasu, M | 1 |
| Matsumoto, M | 1 |
| Okumura, K | 1 |
| Yasuda, K | 1 |
| Akatsuka, H | 1 |
| Kawanami, S | 1 |
| Watanabe, A | 1 |
| Saiga, Y | 1 |
| Ozeki, M | 1 |
| Iijima, I | 1 |
| Levi, M | 1 |
| Tack, CJ | 4 |
| Smits, P | 4 |
| Demacker, PN | 2 |
| Stalenhoef, AF | 2 |
| Park, KS | 1 |
| Abrams-Carter, L | 1 |
| Ong, MK | 1 |
| Lutterman, JA | 1 |
| Skyler, JS | 1 |
| Yamakita, T | 1 |
| Ishii, T | 1 |
| Mori, T | 1 |
| Sato, T | 1 |
| Tanaka, S | 1 |
| Kurimasa, H | 1 |
| Fujita, K | 1 |
| Fujii, S | 1 |
| Granberry, MC | 1 |
| Fonseca, VA | 1 |
| Elkind-Hirsch, KE | 1 |
| McWilliams, RB | 1 |
| Sinha, D | 1 |
| Addya, S | 1 |
| Murer, E | 1 |
| Boden, G | 1 |
| Brown, KK | 1 |
| Blanchard, SG | 1 |
| Cobb, JE | 1 |
| Mook, R | 1 |
| Kaldor, I | 1 |
| Kliewer, SA | 1 |
| Lehmann, JM | 1 |
| Lenhard, JM | 1 |
| Harrington, WW | 1 |
| Novak, PJ | 1 |
| Faison, W | 1 |
| Binz, JG | 1 |
| Hashim, MA | 1 |
| Oliver, WO | 1 |
| Brown, HR | 1 |
| Parks, DJ | 1 |
| Plunket, KD | 1 |
| Tong, WQ | 1 |
| Menius, JA | 1 |
| Adkison, K | 1 |
| Noble, SA | 1 |
| Higa, M | 3 |
| Ravazzola, M | 1 |
| Baetens, D | 2 |
| Orci, L | 2 |
| Van Den Bergh, AJ | 1 |
| Van Den Boogert, HJ | 1 |
| Vervoort, G | 1 |
| Heerschap, A | 1 |
| Oshida, Y | 1 |
| Kako, M | 1 |
| Nakai, N | 1 |
| Shimomura, Y | 1 |
| Li, L | 1 |
| Sato, J | 1 |
| Ohsawa, I | 1 |
| Sato, Y | 2 |
| Grayburn, P | 1 |
| Karim, A | 1 |
| Iwatani, M | 1 |
| Wasada, T | 1 |
| Iwamoto, Y | 1 |
| Kamatani, N | 1 |
| Gottschling-Zeller, H | 1 |
| Röhrig, K | 1 |
| Hauner, H | 1 |
| Ide, T | 1 |
| Nakazawa, T | 1 |
| Mochizuki, T | 1 |
| Murakami, K | 1 |
| Kimura, M | 1 |
| Daimon, M | 1 |
| Tominaga, M | 1 |
| Manaka, H | 1 |
| Sasaki, H | 1 |
| Kato, T | 1 |
| Shibata, T | 1 |
| Takeuchi, S | 1 |
| Yokota, S | 1 |
| Kakimoto, K | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Kadowaki, T | 1 |
| Frias, JP | 1 |
| Yu, JG | 2 |
| Kruszynska, YT | 2 |
| Sobel, BE | 1 |
| Kakuma, T | 1 |
| Wang, Zw | 1 |
| Pan, W | 1 |
| Shimomura, I | 1 |
| Akazawa, S | 1 |
| Sun, F | 1 |
| Ito, M | 1 |
| Kawasaki, E | 1 |
| Eguchi, K | 1 |
| Jia, DM | 1 |
| Tabaru, A | 1 |
| Nakamura, H | 1 |
| Fukumitsu, KI | 1 |
| Akiyama, T | 1 |
| Otsuki, M | 1 |
| Okuda, N | 1 |
| Takishita, S | 1 |
| Omae, T | 1 |
| Dobashi, K | 2 |
| Asayama, K | 2 |
| Nakane, T | 2 |
| Kodera, K | 2 |
| Hayashibe, H | 2 |
| Nakazawa, S | 2 |
| Memon, RA | 1 |
| Tecott, LH | 1 |
| Nonogaki, K | 1 |
| Beigneux, A | 1 |
| Moser, AH | 1 |
| Grunfeld, C | 1 |
| Feingold, KR | 1 |
| Hevener, AL | 1 |
| Reichart, D | 1 |
| Uemura, K | 1 |
| Tamaya, N | 1 |
| Tamagawa, T | 1 |
| Miura, H | 1 |
| Iguchi, A | 1 |
| Nakamura, J | 1 |
| Hotta, N | 1 |
| Iuorno, MJ | 1 |
| Nestler, JE | 1 |
| Katsuki, A | 2 |
| Sumida, Y | 2 |
| Murata, K | 1 |
| Furuta, M | 2 |
| Araki-Sasaki, R | 2 |
| Tsuchihashi, K | 1 |
| Hori, Y | 2 |
| Yano, Y | 2 |
| Gabazza, EC | 2 |
| Adachi, Y | 2 |
| Caldwell, SH | 1 |
| Hespenheide, EE | 1 |
| Redick, JA | 1 |
| Iezzoni, JC | 1 |
| Battle, EH | 1 |
| Sheppard, BL | 1 |
| Ghanim, H | 3 |
| Garg, R | 3 |
| Aljada, A | 3 |
| Mohanty, P | 3 |
| Kumbkarni, Y | 1 |
| Assian, E | 2 |
| Hamouda, W | 2 |
| Dandona, P | 3 |
| Naderali, EK | 1 |
| Pickavance, LC | 1 |
| Wilding, JP | 1 |
| Doyle, PJ | 1 |
| Williams, G | 1 |
| Katoh, S | 1 |
| Hata, S | 1 |
| Matsushima, M | 1 |
| Ikemoto, S | 1 |
| Inoue, Y | 1 |
| Yokoyama, J | 1 |
| Tajima, N | 1 |
| Malacara, JM | 1 |
| Fajardo, ME | 1 |
| Nava, LE | 1 |
| Uchida, N | 1 |
| Maher, J | 1 |
| Friedman, J | 1 |
| Bedoucha, M | 1 |
| Atzpodien, E | 1 |
| Boelsterli, UA | 1 |
| Hayashi, H | 1 |
| Kanai, S | 1 |
| Ichikawa, M | 1 |
| Funakoshi, A | 1 |
| Miyasaka, K | 1 |
| Fürnsinn, C | 1 |
| Nowotny, P | 1 |
| Brunmair, B | 1 |
| Gras, F | 1 |
| Roden, M | 1 |
| Waldhäusl, W | 1 |
| Vierhapper, H | 1 |
| Yamagishi, T | 1 |
| Saito, Y | 1 |
| Nakamura, T | 1 |
| Takeda, S | 1 |
| Kanai, H | 1 |
| Sumino, H | 1 |
| Kuro-o, M | 1 |
| Nabeshima, Y | 1 |
| Kurabayashi, M | 1 |
| Nagai, R | 1 |
| Marra, F | 1 |
| Pastacaldi, S | 1 |
| Montague, CT | 1 |
| Tanaka, T | 1 |
| Nakatani, K | 1 |
| Fonseca, V | 1 |
| Keebler, M | 1 |
| Dicker-Brown, A | 1 |
| Desouza, C | 1 |
| Poirier, LA | 1 |
| Murthy, SN | 1 |
| McNamara, DB | 1 |
| Yoshioka, T | 1 |
| Ushiyama, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)[NCT00819910] | Phase 4 | 41 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Slow recruitment and increase in deployment overseas limiting follow up) | ||
| Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring[NCT00290394] | Phase 4 | 25 participants | Interventional | 2004-03-31 | Completed | ||
| Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes[NCT00194896] | 64 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome[NCT02633488] | 19 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy[NCT00469911] | 18 participants (Actual) | Interventional | 2005-08-31 | Completed | |||
| Comparative Metabolomics in Diabetes Patients From Sri Lanka and Switzerland[NCT05787457] | 34 participants (Actual) | Observational | 2014-07-31 | Terminated (stopped due to Insufficient recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | 7.4 |
| Fenofibrate + Placebo | -2.2 |
| Rosiglitazone +Fenofibrate | 20 |
| Placebo Therapy Daily | 7.6 |
The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone and Placebo | 1.9 |
| Fenofibrate + Placebo | 14.5 |
| Rosiglitazone +Fenofibrate | 5.8 |
| Placebo Therapy Daily | 1.7 |
The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | -0.5 |
| Fenofibrate + Placebo | 2.6 |
| Rosiglitazone + Fenofibrate | 37.3 |
| Placebo Therapy Daily | 13.7 |
The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| AST 1 (aspartate aminotransferase [10-35 U/L]) | AST 12 (aspartate aminotransferase [15-37 U/L]) | ALT 1 (alanine aminotransferase [6-60 U/L]) | ALT 12 (alanine aminotransferase [6-60 U/L]) | |
| Fenofibrate + Placebo | 25.25 | 26.50 | 25.88 | 26.38 |
| Placebo Therapy Daily | 19.88 | 17.88 | 20.88 | 14.88 |
| Rosiglitazone + Placebo | 24.00 | 30.29 | 28.14 | 27.43 |
| Rosiglitazone +Fenofibrate | 24.30 | 19.70 | 24.10 | 21.10 |
Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % Change (Median) | ||
|---|---|---|---|
| Apo AI | Apo AII | Apo CIII | |
| Fenofibrate + Placebo | 13 | 3.4 | -4.35 |
| Placebo Therapy Daily | 5 | -3.5 | -2.3 |
| Rosiglitazone + Placebo | -1.00 | 10.25 | 0.30 |
| Rosiglitazone +Fenofibrate | 1 | 7.2 | -5.3 |
Number of participants positive for T cell reactivity to islet proteins at 36 months. (NCT00194896)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Rosiglitazone Autoantibody Positive | 1 |
| Rosiglitazone Autoantibody Negative | 2 |
| Glyburide Autoantibody Positive | 2 |
| Glyburide Autoantibody Negative | 3 |
Changes in beta cell function assessed by fasting and stimulated C-peptide measured at 36 months. (NCT00194896)
Timeframe: 36 months
| Intervention | ng per ml (Mean) | |
|---|---|---|
| Fasting C-peptide | Glucagon Stimulated C-peptide | |
| Glyburide Autoantibody Negative | 0.3 | 0.3 |
| Glyburide Autoantibody Positive | 0.1 | 3.1 |
| Rosiglitazone Autoantibody Negative | -1.4 | -2.8 |
| Rosiglitazone Autoantibody Positive | -0.4 | -0.6 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature (NCT02633488)
Timeframe: before and after 12 weeks on placebo or metformin
| Intervention | percentage of artery dilation (Mean) |
|---|---|
| Pre and Post Placebo 12 Weeks | 6.1 |
| Pre and Post Metformin 12 Weeks | 6.2 |
Participants first had MRS spectroscopy then the MRS spectroscopy images were compared to endomyocardial biopsy (NCT00469911)
Timeframe: 2 to 10 days
| Intervention | correlation co-efficient (Number) |
|---|---|
| Heart Transplant Patients | 0.97 |
15 reviews available for troglitazone and Obesity
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Current best treatment for non-alcoholic fatty liver disease.
Topics: Antioxidants; Chromans; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Fatty L | 2003 |
Prevention of type 2 diabetes.
Topics: Acarbose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglyc | 2002 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
Prevention of type 2 diabetes.
Topics: Acarbose; Birth Weight; Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2 | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa | 2005 |
Effects of troglitazone on insulin sensitivity.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Gl | 1996 |
[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Topics: Adult; Aged; Chromans; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing | 1997 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; H | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Mice | 2000 |
The polycystic ovary syndrome: treatment with insulin sensitizing agents.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Ovar | 1999 |
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chro | 2002 |
18 trials available for troglitazone and Obesity
| Article | Year |
|---|---|
First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.
Topics: Behavior Therapy; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Fe | 2008 |
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
Topics: Blood Glucose; Blood Pressure; Chromans; Endothelium, Vascular; Female; Humans; Hyperandrogenism; Hy | 2003 |
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Aged; Biopsy; Chromans; Culture Media, Conditioned; | 2003 |
Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.
Topics: Adult; Aged; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fe | 2003 |
Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.
Topics: Blood Glucose; Chromans; Denmark; Diabetes Mellitus, Type 2; Family; Glucose Clamp Technique; Glucos | 2004 |
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.
Topics: Adult; Aged; Biopsy; Blood Glucose; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Female | 2006 |
The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.
Topics: Adult; Alanine; Amino Acid Substitution; Body Composition; Chromans; Diabetes Mellitus, Type 2; Diet | 2007 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Leptin concentrations in the polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Chromans; Double-Blind Method; Female; Humans; Hyperinsulinism; Hypoglycemic | 1997 |
Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.
Topics: Adult; Blood Glucose; Body Weight; Cholesterol, LDL; Chromans; Cross-Over Studies; Double-Blind Meth | 1998 |
Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Topics: Acetylcholine; Adult; Analysis of Variance; Biomarkers; Blood Glucose; Cardiovascular System; Case-C | 1998 |
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, | 1999 |
Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Topics: Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Ag | 1999 |
Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Chromans; Diabetes Mellitus; Diabetes | 2000 |
Efficacy of troglitazone on body fat distribution in type 2 diabetes.
Topics: Adipose Tissue; Body Mass Index; C-Peptide; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 2000 |
Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Topics: Adipose Tissue; Aged; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2001 |
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.
Topics: Chromans; Clomiphene; Estrogens; Feedback, Physiological; Female; Follicle Stimulating Hormone; Gona | 2001 |
Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?
Topics: Adult; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Cholesterol; Chr | 2001 |
63 other studies available for troglitazone and Obesity
| Article | Year |
|---|---|
Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments.
Topics: Adipogenesis; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; M | 2019 |
A New Agonist for Peroxisome Proliferation-activated Receptor γ (PPARγ), Fraglide-1 from Zhenjiang Fragrant Vinegar: Screening and Characterization Based on Cell Culture Experiments.
Topics: 4-Butyrolactone; Acetic Acid; Animals; Anti-Obesity Agents; Cells, Cultured; Chlorocebus aethiops; C | 2017 |
Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Body Weight; Caloric Restriction; Chroma | 2002 |
Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats.
Topics: Adipose Tissue; Animals; Cell Fractionation; Chromans; Diabetes Mellitus; Disease Models, Animal; Hy | 2002 |
Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo.
Topics: Adipose Tissue; Animals; Chromans; Esterification; Fasting; Fatty Acids, Nonesterified; Glycerol; Hy | 2003 |
Altered renal microvascular response in Zucker obese rats.
Topics: Acetylcholine; Animals; Arterioles; Blood Pressure; Chromans; Hydronephrosis; In Vitro Techniques; I | 2002 |
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Animals, Genetically Modified; Blotting, Weste | 2004 |
Causation of type 2 diabetes -- the Gordian knot unravels.
Topics: Adenosine Triphosphate; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin; Islet | 2004 |
Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone.
Topics: Adenylate Kinase; Animals; Cells, Cultured; Chromans; Diabetes Mellitus; Fatty Acids, Nonesterified; | 2005 |
Insulin resistance contributes to obesity-related proteinuria.
Topics: Adult; Biopsy; Blood Glucose; Blood Pressure; Body Mass Index; Chromans; Creatinine; Female; Follow- | 2005 |
Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Chromans; Complement C1q; Complement C1r; Complement C1s; Com | 2007 |
Exacerbation of acidosis during ischemia and reperfusion arrhythmia in hearts from type 2 Diabetic Otsuka Long-Evans Tokushima Fatty rats.
Topics: Animals; Arrhythmias, Cardiac; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Diabetic Ketoacid | 2007 |
Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-gamma activation in +db/+m and +db/+db mice.
Topics: Abdominal Fat; Adipocytes; Animals; Aorta, Thoracic; Carbohydrate Metabolism; Chromans; Diabetes Mel | 2007 |
Regulation of retinol binding protein 4 production in primary human adipocytes by adiponectin, troglitazone and TNF-alpha.
Topics: Adipocytes; Adiponectin; Chromans; Diabetes Mellitus; Humans; Obesity; Retinol-Binding Proteins, Pla | 2007 |
Insulin resistance and the prevention of diabetes mellitus.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Re | 1994 |
Antihypertensive effects of CS-045 treatment in obese Zucker rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Chromans; Diuresis; Fe | 1993 |
Effect of troglitazone on leptin production. Studies in vitro and in human subjects.
Topics: Adipocytes; Adult; Animals; Blood Glucose; Cells, Cultured; Chromans; Fasting; Female; Glucose; Huma | 1996 |
Glitazones and NIDDM.
Topics: Animals; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Obesit | 1997 |
Troglitazone for non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dose-Response Relation | 1997 |
Is troglitazone a real indication for obese subjects with impaired glucose tolerance?
Topics: Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Obesity; Thia | 1997 |
Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats.
Topics: Animals; Chromans; Hypoglycemic Agents; In Vitro Techniques; Ion Channels; Islets of Langerhans; Mal | 1997 |
Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity.
Topics: Animals; Cell Survival; Cells, Cultured; Chromans; Diabetes Mellitus, Type 1; Fatty Acids, Nonesteri | 1997 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglyc | 1997 |
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes.
Topics: Animals; Apoptosis; Cells, Cultured; Ceramides; Chromans; Coenzyme A Ligases; Diabetes Mellitus; Dia | 1998 |
Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects.
Topics: Adult; Cells, Cultured; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucose Tra | 1998 |
Targeted glycemic control in type 2 diabetes.
Topics: Aged; Algorithms; Anti-Obesity Agents; Biguanides; Blood Glucose; Blood Glucose Self-Monitoring; Chr | 1998 |
Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
Topics: Adolescent; Blood Glucose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intoleran | 1998 |
Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome.
Topics: Acanthosis Nigricans; Adult; Blood Glucose; Chromans; Female; Gonadal Steroid Hormones; Humans; Hypo | 1999 |
15-Deoxy-delta(12,14) prostaglandin J2: a putative endogenous promoter of adipogenesis suppresses the ob gene.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Chromans; DNA-Bin | 1999 |
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Topics: Animals; Benzophenones; Chromans; Clone Cells; Diabetes Mellitus, Experimental; Glucose Clamp Techni | 1999 |
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus; Eating; Hypoglycemic Agents; Islet | 1999 |
Assessment of human muscle glycogen synthesis and total glucose content by in vivo 13C MRS.
Topics: Adult; Carbon Isotopes; Chromans; Glucose; Glucose Clamp Technique; Glycogen; Humans; Hypoglycemic A | 2000 |
Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Animals; Blood Glucose; Body Weight; Chromans; Eating; Glucose Cla | 1999 |
Lipotoxic heart disease in obese rats: implications for human obesity.
Topics: Age Factors; Animals; Apoptosis; Blood Glucose; Body Weight; Chromans; DNA Fragmentation; Echocardio | 2000 |
Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes.
Topics: Adipocytes; Adult; Cell Differentiation; Cells, Cultured; Chromans; Culture Media; Female; Humans; M | 2000 |
Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.
Topics: Administration, Oral; Animals; Chromans; Diabetes Mellitus; Fatty Acids; Hypoglycemic Agents; Liver; | 2000 |
Thiazolidinediones exert different effects on insulin resistance between dexamethasone-treated rats and wistar fatty rats.
Topics: Animals; Chromans; Dexamethasone; Drug Combinations; Glucocorticoids; Glucose; Glucose Clamp Techniq | 2000 |
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chro | 2000 |
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Topics: Adult; Arteriosclerosis; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Fibrinolysis; G | 2000 |
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.
Topics: Adenoviridae; Animals; CCAAT-Enhancer-Binding Proteins; Chromans; DNA-Binding Proteins; Genetic Vect | 2000 |
Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus | 2000 |
Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Chromans; Diet, Reducing; Female; Humans; Hypertension; Hypoglycemic Ag | 2000 |
Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Chromans; Escherichia coli; Gene Expression Re | 2000 |
Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the li
Topics: Adipose Tissue; Animals; Blotting, Northern; Chromans; Diabetes Mellitus; Gene Expression Regulation | 2000 |
Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat.
Topics: Animals; Chromans; Female; Glucose Clamp Technique; Glucose Transporter Type 4; Insulin; Insulin Rec | 2000 |
Dietary fat-induced increase in blood pressure and insulin resistance in rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Body Weight; Chromans; Dietary Carbohydrates | 2000 |
Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobi | 2000 |
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Chromans; Fatty Liver; Female; Humans; Hypoglycemic Agents; Obesity; Pi | 2001 |
Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.
Topics: Adult; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; C-Reactive Protein; Cell Nucleus; | 2001 |
Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover.
Topics: Animals; Apoptosis; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Hypoglycemic Agents; Islets of | 2001 |
Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats.
Topics: Acetylcholine; Animals; Blood Glucose; Body Weight; Chromans; Diet; Dose-Response Relationship, Drug | 2001 |
Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue.
Topics: Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Body Weight; Chromans; Enzyme-Linked Immu | 2001 |
Antidiabetic treatment for NASH?
Topics: Animals; CCAAT-Enhancer-Binding Proteins; Chromans; Diabetes Mellitus; DNA-Binding Proteins; Fatty L | 2001 |
Troglitazone reduces the expression of PPARgamma while stimulating that of PPARalpha in mononuclear cells in obese subjects.
Topics: Adult; Antioxidants; Blood Glucose; Blotting, Western; Chromans; Female; Humans; Insulin; Leukocytes | 2001 |
Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus; Fatty Liver; Gene Expression; Hypoglycemic Agents; Liver; Male | 2001 |
Increased lymphatic lipid transport in genetically diabetic obese rats.
Topics: Animals; Bile Acids and Salts; Body Weight; Carrier Proteins; Chromans; Diabetes Mellitus; Diabetes | 2002 |
Thiazolidinediones influence plasma steroids of male obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Glucose; Hormones; Insulin; Male; Muscle, Skeletal; O | 2002 |
Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors.
Topics: Animals; Arteriosclerosis; Chromans; Endothelium, Vascular; Glucuronidase; Hypertension; Kidney; Klo | 2001 |
A treatment for Mr WP: thiazolidinediones after troglitazone.
Topics: Aged; Animals; Body Mass Index; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hem | 2002 |
Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.
Topics: Adipose Tissue; Animals; Blood Glucose; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, | 2002 |
The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats.
Topics: Animals; Chromans; Cystathionine beta-Synthase; Erythrocytes; Female; Homocysteine; Hypoglycemic Age | 2002 |
Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Topics: Adipose Tissue; Animals; Benzopyrans; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus, Expe | 1988 |